| I-035 Rolien Bosch From In Vitro Efficacy to Long-term HbA1c Response for GLP-1R/GlucagonR Agonism using the 4GI-HbA1c Systems Model Wednesday 10:20-11:50 |
| III-069 Kristin C. Carlsson Petri TransCon CNP (Navepegritide): A semi-mechanistic model to describe the prolonged half-life of C-type natriuretic peptide through TransConTM technology Thursday 09:50-11:20 |
| IV-005 Chaozhuang Shen A Physiologically-Based Quantitative Systems Pharmacology (PB-QSP) Model for Individualized Prediction of Treatment Outcomes with Alogliptin in the Renal Impairment Population Thursday 15:00-16:30 |
| IV-091 Jan-Georg Wojtyniak Population Pharmacokinetics of Survodutide in Subjects with Overweight or Obesity with and without Type 2 Diabetes Mellitus Based on Phase I and Phase II Data Thursday 15:00-16:30 |
